Answers are grounded in this paper and cite their sources.
Dendritic cells (DCs) are potent antigen-presenting cells that constitute a major component of the immune system's role in the recognition, elimination, and tolerance of cancer. The unique immunologic capabilities of DCs have recently been harnessed for therapeutic use with the creation of DC-based anti-tumor vaccines, several of which have moved into testing in clinical trials for hematologic malignancies. This review summarizes how treatment strategies using DC-based anti-tumor vaccines are advancing immunotherapeutic options for these diseases.
No takes yet. Share an insight, caveat, or question.
Weinstock et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: